DISCLAIMER
tion method used. This idea changed by the work of different groups, who pointed to the importance of phospholipid binding plasma proteins, such as ␤ 2 -glycoprotein I (␤ 2 GPI), for the binding of aPL (5) (6) (7) (8) .
␤ 2 GPI, also known as apolipoprotein H, is a plasma glycoprotein, which consists of 326 amino acids, has a molecular mass of approximately 50 kD and has five potential glycosylation sites (9) . The protein comprises 5 repeating domains of about 60-80 amino acids, in which cysteine, proline and tryptophane residues appear to be highly conserved. Each domain resembles the so called short consensus repeats (SCR) or Sushi domains (10, 11) .
Although there is considerable insight in the structure of ␤ 2 GPI, little is known about the physiological function of the protein in human plasma. The plasma concentration of ␤ 2 GPI is approximately 160 g/ ml (3.8 M) of which 40% is bound to lipoproteins, especially chylomicrons and VLDL (12, 13) . Besides binding to lipoproteins, ␤ 2 GPI can also bind to negatively charged surfaces (14) (15) (16) such as heparin, negatively charged phospholipids and DNA. In vitro, ␤ 2 GPI shows a variety of anticoagulant properties. ␤ 2 GPI inhibits contact activation (17) (18) (19) , it inhibits tenase and prothrombinase activity on activated human platelets or phospholipid vesicles (20) (21) (22) and it inhibits ADP-induced platelet aggregation (14, 16) . ␤ 2 GPI also has procoagulant activities, because it was shown that ␤ 2 GPI can inhibit the anticoagulant activity of activated protein C (23, 24) . However, the physiological importance of ␤ 2 GPI as a regulator of coagulation is disputable, because individuals without detectable levels of ␤ 2 GPI do not suffer from clotting or bleeding complications (25, 26) .
In this study, we describe that during purification of ␤ 2 GPI from human plasma using heparin-Sepharose affinity chromatography, proteolytical cleavage of ␤ 2 GPI, between residues Lys317 and Thr318, occurs. We found that plasmin, trypsin and elastase can cause this cleavage in vitro. With monoclonal antibodies raised against cleaved and intact ␤ 2 GPI, levels of the different forms of ␤ 2 GPI were measured in plasmas of healthy controls, in plasmas of patients with disseminated intravascular coagulation (DIC) and in plasmas of patients treated with streptokinase. From the results it can be concluded that ␤ 2 GPI is cleaved in vivo upon activation of fibrinolysis and that plasmin is most likely to be responsible for this in vivo modification of ␤ 2 GPI.
Methods

Materials
The different Sepharoses used and horseradish peroxidase labeled sheep anti-M13 antibody (␣-M13-PO) were from Pharmacia Biotech (Uppsala, Sweden). High binding ELISA plates (strip plate, cat.no. 9102) and regular 96-well ELISA plates were from Costar (Cambridge, MA, USA). PNGase F was from New England Biolabs (Beverly, MA, USA). BCA protein assay kit was from Pierce (Rockford, IL, USA 1, 3 From the Departments of 1 Haematology and 2 Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands and the 3 Institute of Biomembranes, Utrecht University, The Netherlands Summary ␤ 2 -glycoprotein I (␤ 2 GPI) is a plasma glycoprotein with unknown physiological function(s). In in vitro experiments it has been demonstrated that ␤ 2 GPI has both anticoagulant properties, such as the inhibition of factor X and prothrombin activation and procoagulant properties, such as the inhibition of the anticoagulant activity of activated protein C. Besides this, ␤ 2 GPI bound to cardiolipin is recognized by antiphospholipid antibodies (aPL).
In this study we demonstrate that ␤ 2 GPI is very sensitive for cleavage between Lys317 and Thr318 by plasmin, resulting in two immunologically different cleaved forms. In vitro experiments show that these plasmin cleaved forms of ␤ 2 GPI bind to negatively charged phospholipids with much lower affinity compared to intact ␤ 2 GPI. Similar to plasmin, trypsin and elastase can also induce this proteolytical cleavage in ␤ 2 GPI, whereas thrombin and factor Xa do not cleave ␤ 2 GPI. The in vivo occurrence of the proteolytical cleavage was demonstrated by the finding that in plasmas of patients with disseminated intravascular coagulation (DIC) and in plasmas of patients treated with streptokinase, significant amounts of cleaved ␤ 2 GPI (up to 12 g/ml) are present. During the development of DIC, the increase in levels of cleaved ␤ 2 GPI is accompanied by a 70% decrease in the levels of intact ␤ 2 GPI, whereas in streptokinase treated patients levels of intact ␤ 2 GPI stay within the normal range.
This study demonstrates for the first time that during in vivo activation of fibrinolysis ␤ 2 GPI is cleaved, which results in the formation of a form of ␤ 2 GPI with much lower affinity for negatively charged phospholipids. Plasmin is most likely responsible for this modification.
Introduction
The presence of antiphospholipid antibodies (aPL) in plasmas of patients with systemic lupus erythematosus (SLE) is strongly correlated with a history of venous and arterial thrombosis, recurrent fetal loss and thrombocytopenia (1) (2) (3) (4) . This clinical-serological entity is called the antiphospholipid syndrome (APS). Till 1990, it was generally accepted that aPL are directed against negatively charged phospholipids and that aPL could be divided into different subclasses named anticardiolipin antibodies (aCL) and lupus anticoagulant (LAC), based on the detec-mark). Protifar was from Nutricia (Zoetermeer, The Netherlands). E. coli strain XL1-Blue and helper phage VCS-M13 were from Stratagene (La Jolla, CA, USA). Polyclonal rabbit anti-␤ 2 GPI-antibodies (PoAb) were from Behring (Amersfoort, The Netherlands). (Peroxidase labeled) rabbit anti mouse immunoglobulins (RAMPO or R␣M) and peroxidase labeled swine anti rabbit immunoglobulins (SWARPO) were from Dako (Glostrup, Denmark). Soybean Trypsin Inhibitor (SBTI), benzamidin, polybrene, phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine were from Sigma (St. Louis, MO, USA). PVDF Immobilon-P Transfer membranes were from Millipore Corporation (Bedford, MA, USA). S2251 was from Chromogenix (Mölndal, Sweden). Streptokinase (Streptase ® ) was from Hoechst (Amsterdam, The Netherlands). Alkaline phosphatase conjugated goat anti human IgG was from Tago (Burlingame, CA, USA). Trypsin was from Worthington Biochemical Corp. (Freehold, NJ, USA). Elastase and automated STA APTT kit was from Boehringer Mannheim (Mannheim, Germany). Nyocard D-dimer kit was from Nycomed UK Ltd (Birmingham, UK).
Blood Collection
Blood samples were collected by venipuncture using evacuated tubes containing 3.8% trisodium citrate (0.129 M) as the anticoagulant (9 :1, v/v). To obtain platelet poor plasma the samples were centrifuged twice at 2000 ϫ g for 10 min at 4°C. Plasma samples were stored at -50°C until use.
Healthy Controls and Patients
Healthy controls. Plasmas of 65 healthy controls (40 females and 25 males) were used in this study. The mean age was 32 years (range 23-51 years).
Sepsis/DIC patients. 15 sepsis/DIC patients were recruited from a primary medical-surgical intensive care unit. Their median age was 60 years (range 23-80 years). Patients were identified as having sepsis on the basis of temperature (>38.3°C or <35.0°C) with a systolic blood pressure 20 mmHg below their usual level. The sepsis syndrome was verified by positive blood cultures and/or a specific site of infection. Mean platelet count was 130*10 9 /l (range 18*10 9 -372*10 9 ) (27) . All sepsis patients included in this study suffered from disseminated intravascular coagulation (DIC), as monitored by the presence of a prolonged activated partial thromboplastin time (APTT), prolonged prothrombin time (PT), prolonged thrombin time (TT) and elevated levels of D-dimer and F1+2.
Streptokinase treated patients. Plasmas of four patients who were treated with streptokinase (1.5*10 6 units) after acute myocardial infarction were included in this study. Samples were taken 1 h after streptokinase administration.
An almost drowned person. Multiple plasma samples were taken from a person (male, age 22 years) who was hospitalized immediately after being rescued from drowning. The patient developed severe DIC.
Activated Partial Thromboplastin Time (APTT)
APTT clotting times were measured in citrated plasma using the automated STA APTT kit, according to instructions of the manufacturer.
Levels of D-dimer
D-dimer levels were measured in citrated plasma using NyoCard D-dimer kit, according to the instructions of the manufacturer.
Proteins
␤ 2 GPI was purified from freshly frozen citrated human plasma (obtained from the local blood bank) as described before (3), with a few modifications. Briefly, human plasma was quickly thawed at 37°C and 40 g/ml Soybean Trypsin Inhibitor (SBTI), 1 mM benzamidin, 1 mM EDTA and 0.0025% polybrene were added to the plasma. The plasma was successively applied to a DEAE-Sephadex A50 column, protein G-Sepharose column and a S-Sepharose column. Afterwards, eluted proteins were applied to a heparin-Sepharose column. Bound phospholipid contaminations were eluted using 20 mM Tris/ 50 mM NaCl/0.1% Triton X-100 (pH 8.3). The column was washed with the same Tris buffer without Triton X-100 and bound proteins were eluted with a linear salt gradient from 50 mM to 350 mM NaCl in 20 mM Tris (pH 8.3). The peak fractions were analyzed by SDS-PAGE, and the presence of ␤ 2 GPI was demonstrated after the proteins were transferred to a PVDF Immobilon-P Transfer membrane by blotting with rabbit anti-human ␤ 2 GPI-antibodies. Protein concentration was determined using a BCA protein assay kit according to the manufacturer's instructions with bovine serum albumin (BSA) as a standard.
Plasminogen [purified from freshly frozen citrated human plasma, as described elsewhere (28) ] was a kind gift from Dr. Peter A. Kr. von dem Borne (University Hospital Utrecht, The Netherlands). Plasminogen was activated by using a plasminogen-streptokinase complex (29) . Plasmin concentration was determined using a BCA protein assay kit according to the manufacturer's instructions with BSA as a standard. The final preparation was homogeneous by SDS-PAGE.
Factor X was purified from human plasma with a monoclonal anti-factor Xantibody as described by Hackeng et al. (30) . Factor X was activated by incubation with immobilized Russell viper venom as described by Bock et al. (31) .
PNGase F Treatment
To remove all N-linked carbohydrate side chains from ␤ 2 GPI, the protein (150 g/ml) was incubated overnight at 37°C with PNGase F under reducing conditions, according to the instructions of the manufacturer.
N-terminal Sequence Analysis
␤ 2 GPI was subjected to 12% SDS-PAGE followed by Western blotting, according to instructions from the Sequence Centre Utrecht (Centre for Biomembranes and Lipid Enzymology, Department Biochemistry of Lipids, Utrecht, The Netherlands). The protein band was cut from the blot and the N-terminal sequence was determined by automated Edman degradation using a gas phase sequenator (Applied Biosystems model 476A) by the Sequence Centre Utrecht.
Production and Purification of Monoclonal Antibodies against ␤ 2 GPI
BALB/c mice were immunized with a 1:1 mixture of ␤ 2 GPI *1 and ␤ 2 GPI intact according to standard methods. Spleen cells were fused with Ag 8.653 myeloma cells. Fusion and hybridoma selection were performed according to standard procedures. Culture supernatants were screened for the presence of specific antibodies by an ELISA in which ␤ 2 GPI was used as antigen. Bound antibodies were detected with peroxidase-labeled rabbit antibodies against mouse immunoglobulins (RAMPO). Positive clones were subcloned by limiting dilution and tested. This resulted in two clones (from different fusions), one named NIK-13A10 and one named OCK-4F3. MoAbs were purified from culture medium by passing the medium through a 3.5 ml R␣M (rabbit antibodies against mouse immunoglobulins)-Sepharose column. 9 mg R␣M was coupled to 3.5 ml CNBr-activated Sepharose according to the instructions of the manufacturer. Bound proteins were eluted with 3M KSCN in TBS (50 mM Tris/ 150 mM NaCl). Antibody containing fractions were combined, dialyzed against TBS and applied to a protein G-Sepharose FF-column (10 ml) for concentration. Bound proteins were eluted with 0.1 M glycine (pH 2.7) and antibody containing fractions were pooled and dialyzed against TBS. Purified antibodies were stored at -20°C until use.
Selection of Phage-antibodies against ␤ 2 GPI
The phage display library used for this study was constructed as described before (32) and was kindly provided by Dr. J. de Kruif (Department of Immunology, Utrecht University, The Netherlands). Phages which express human single chain Fv antibody fragments against ␤ 2 GPI intact on the surface were selected from the phage display library using a selection procedure as described before (32), in which ␤ 2 GPI intact (50 g/ml in TBS, pH 7.4) was coated on MaxiSorp tubes overnight at 4°C. The selected phages, that recognize coated ␤ 2 GPI intact were used to infect bacteria. E. coli strain XL1-Blue were infected with the eluted phage antibodies and grown as described before (33) . The assembling of new phage particles by the infected XL1-Blue strain was accomplished using helper phage VCS-M13. Phage antibodies were isolated from the XL1-Blue culture by polyethylene glycol (PEG)/NaCl precipitation. After the last precipitation the phage containing pellet was dissolved in 3 ml PBS/1% BSA and stored at 4°C.
After each selection round, obtained phage antibodies were screened for their specific binding to ␤ 2 GPI intact using an ELISA, in which ␤ 2 GPI intact (10 g/ml in TBS, 100 l/well) was coated on high binding 96 wells ELISA plates. Wells were blocked with TBS/3% BSA/0.1% Tween-20 (150 l/well) for 2 h at 37°C and wells were incubated with phage antibodies at various dilutions for 1.5 h at 37°C. Afterwards bound phage antibodies were detected with 1: 2500 diluted horseradish peroxidase labeled sheep anti-M13 antibody (␣-M13-PO) for 1.5 h at 37°C and developed with staining solution (100 l/ well) consisting of 0.4 mg/ml o-phenylenediamine (OPD) and 0.002% H 2 O 2 in 100 mM phosphate/50 mM citric acid buffer (pH 5.0). The reaction was stopped by the addition of 1 M H 2 SO 4 (50 l/well) and absorbance was measured at 490 nm in a multiscan photometer (Vmax reader, Molecular Devices, CA, USA). Dilutions were made in TBS/3% BSA/0.1% Tween-20 and after each incubation step, the wells were washed three times with TBS/0.1% Tween-20.
To obtain highly specific anti-␤ 2 GPI intact -phage antibodies, the selection procedure was repeated three times. After the last selection round, individual colonies were used to prepare monoclonal phage antibodies, as described before (32) . This procedure resulted in a monoclonal anti-␤ 2 GPI intact -phage antibody, designated phage-F3.
Specificity of Different Monoclonal anti-␤ 2 GPI-antibodies for Cleaved and Intact ␤ 2 GPI Preparations
Recognition of cleaved and intact ␤ 2 GPI by phage-F3 antibodies, murine MoAbs 13A10, 4F3 and 2B2 (the latter was a generous gift of Dr. A. Tincani, Spedali Civili, Brescia, Italy) or polyclonal rabbit anti-␤ 2 GPI-antibodies (PoAb) was tested in an ELISA. High binding ELISA plates were coated with increasing concentrations of purified ␤ 2 GPI (100 l/well) in TBS. Wells were blocked with 150 l/well blocking buffer (TBS/3% BSA/0.1% Tween-20) for 2 h at 37°C. Afterwards wells were incubated with 50 l/well phage-F3 antibodies (1: 50 diluted), 13A10 (3 g/ml), 4F3 (3 g/ml), 2B2 (3 g/ml) or PoAb (3 g/ml) for 1.5 h at 37°C. Bound phage-F3 antibodies were incubated with ␣-M13-PO (1: 2500 diluted), bound MoAbs with RAMPO (1:1000 diluted) and bound PoAbs with peroxidase labeled swine anti rabbit antibodies (SWARPO, 1:1000 diluted) for 1.5 h at 37°C. Staining procedure was performed with staining solution (100 l/well) consisting of 0.4 mg/ml o-phenylenediamine (OPD) and 0.002% H 2 O 2 in 100 mM phosphate/50 mM citric acid buffer (pH 5.0). The reaction was stopped by the addition of 1 M H 2 SO 4 (50 l/well) and absorbance was measured at 490 nm. Between every incubation, wells were washed three times with TBS/0.1% Tween-20. All dilutions were made in blocking buffer.
Purification of IgG from Plasma
From the plasma of a SLE-patient with high levels of anti-␤ 2 GPI-IgG (122%) and aCL-IgG (>100 GPL), without anti-␤ 2 GPI-IgM and aCL-IgM antibodies (3) total IgG was purified with protein G-Sepharose according to the manufacturer's instructions.
Binding of Patient IgG to Immobilized ␤ 2 GPI
The binding of purified patient IgG to immobilized ␤ 2 GPI was tested as described before (3), using the ELISA for the detection of anti-␤ 2 GPI-antibodies in plasma. Briefly, ␤ 2 GPI was coated on high binding ELISA plates. After blocking aspecific binding sites, wells were incubated with 100 g/ml purified patient IgG, followed by incubation with alkaline phosphatase conjugated goat
Detection of ␤ 2 GPI Levels in Plasma with ELISA
Total ␤ 2 GPI (cleaved and intact ␤ 2 GPI) levels in plasma were detected with an ELISA in which 100 l/well of a solution containing 3 g/ml MoAb 2B2 (in 15 mM Na 2 CO 3 .10H 2 O, 35 mM NaHCO 3 , pH 9.6) was coated on 96-wells ELISA plates overnight at 4°C. Afterwards, wells were blocked with TBS/3% BSA/0.1% Tween-20, followed by successive incubations with 1:1000 diluted plasmas (50 l/well, 1.5 h at 37°C) and 50 l/well PoAb (3 g/ml; 1 h at 37°C). Bound proteins were detected with 1:1000 diluted SWARPO (50 l/ well) and developed using OPD. Purified ␤ 2 GPI intact (5 ng/ml-1 g/ml) was used as a standard.
For the selective detection of ␤ 2 GPI intact a similar approach was used, in which phage-F3 antibodies (1: 50 diluted) instead of PoAb and ␣-M13-PO (1: 2500 diluted) instead of SWARPO were used.
For the selective detection of ␤ 2 GPI *1 levels in plasma, 96-wells ELISA plates were coated with MoAb 13A10 instead of MoAb 2B2. After blocking, wells were incubated with 50 l/well 1: 5 diluted plasmas for 1.5 h at 37°C, followed by 50 l/well 3 g/ml PoAb for 1 h at 37°C. Bound antibodies were detected with 100 l/well 1:1000 diluted SWARPO and developed using OPD. Purified ␤ 2 GPI *1 (10 ng/ml-1 g/ml) was as a standard.
Dilutions were made in TBS/3% BSA/0.1% Tween-20 and after each incubation, wells were washed three times with TBS/0.1% Tween-20.
Proteolytical Cleavage of ␤ 2 GPI
In order to investigate the proteolytical cleavage of ␤ 2 GPI, the effect of plasmin on ␤ 2 GPI was studied in solution and when ␤ 2 GPI was immobilized on high binding ELISA plates.
1. The effect of plasmin on ␤ 2 GPI in solution. ␤ 2 GPI intact (200 g/ml) was incubated with 0.2 M plasmin in TBS at 37°C. At various time intervals, 10 l samples were taken from the incubation mixture, treated with PNGase F and subjected to 12% SDS-PAGE under reducing conditions. The proteins were visualized by Coommassie Brilliant Blue staining.
2. The effect of plasmin, trypsin, elastase, factor Xa and ␣-thrombin on immobilized ␤ 2 GPI. ␤ 2 GPI intact (5 g/ml) was coated on high binding 96-wells ELISA plates as described before. Afterwards, the wells were incubated with increasing concentrations of plasmin (0-0.2 M), trypsin (0-0.5 M), elastase (0-0.5 M), factor Xa (0-50 nM) or ␣-thrombin (0-0.5 M) (a generous gift of Dr. Walter Kisiel, University of New Mexico, Albuquerque, NM, USA) in TBS/3% BSA/3 mM CaCl 2 for 90 min at 37°C. The different forms of ␤ 2 GPI on the surface were measured using MoAb 4F3, MoAb 13A10 or phage-F3, followed by RAMPO or anti-M13-PO, as described before.
Preparation of Phospholipid Vesicles
Phospholipid vesicles containing 20% phosphatidylserine, 40% phosphatidylcholine and 40% phosphatidylethanolamine were prepared according to Brunner et al. (34) , with some modifications as described by Van Wijnen et al. (35) . The phospholipid content of the fractions was determined by phosphate analysis (36) .
Binding of ␤ 2 GPI to Phospholipids
Binding of ␤ 2 GPI to PS/PC/PE vesicles was tested in a solid phase binding assay. High binding ELISA plates were coated with PS/PC/PE vesicles (25 M in TBS; 50 l/well) overnight at 4°C. Wells were blocked with 150 l/well TBS/0.5% gelatine for 2 h at 37°C. After blocking, wells were incubated with the different ␤ 2 GPI preparations (50 l/well) for 1.5 h at 37°C, followed by incubation with MoAb 2B2 (3 g/ml; 50 l/well; 1.5 h at 37°C). Afterwards, the wells were incubated with RAMPO (1:1000 diluted) followed by staining procedure usin OPD. All samples were diluted in TBS/0.5% gelatine and after each incubation step, wells were washed three times with TBS. Non-specific binding was determined in wells where phospholipids were absent.
Binding of Human anti-␤ 2 GPI-antibodies to Cardiolipin Bound ␤ 2 GPI
To determine whether anti-␤ 2 GPI-antibodies recognize ␤ 2 GPI which is bound to coated cardiolipin (CL), an aCL-ELISA was performed as described previously (3), with a few modifications. Briefly, CL (5 g/well) was coated on high binding 96-well ELISA plates. Wells were blocked with blocking buffer (TBS/0.1% gelatine/0.5 mg/ml purified horse-IgG) and incubated with 100 g/ ml purified patient IgG in the presence of the different forms of 2GPI (0-50 g/ ml) for 1.5 h at 37°C. Binding of human-IgGs was visualized as described before. All dilutions were made in blocking buffer and after each incubation the wells were washed three times with TBS.
Results
Purification and Characterization of ␤ 2 GPI from Normal Human Plasma
The final step in our purification of ␤ 2 GPI from plasma is the elution of ␤ 2 GPI from a heparin-Sepharose column with a linear salt gradient. This procedure results in three separate peaks at 115 mM (␤ 2 GPI-1, fraction 16-26), 150 mM (␤ 2 GPI-2, fraction 33-36) and 200 mM NaCl (␤ 2 GPI-3, fraction 47-56), respectively (Fig. 1) . The mutual ratio of the three peaks varied between purifications.
The three protein preparations were analyzed by SDS-PAGE under (non) reducing conditions, after PNGase F treatment (which removes all N-linked carbohydrate side chains) and by Western blotting (Fig. 2) . Under non-reducing and reducing conditions the three protein preparations showed a triplet of a molecular weight of about 42 kDa and 51 kDa, respectively. Western blotting analysis showed that all three protein preparations reacted with polyclonal rabbit anti human ␤ 2 GPI antibodies. After treatment with PNGase F under reducing conditions the three ␤ 2 GPI preparations showed a single band with a molecular weight of approximately 38 kDa for ␤ 2 GPI-1 and ␤ 2 GPI-2, whereas for ␤ 2 GPI-3 the molecular weight was about 1 kDa higher. The enzyme PNGase F is represented by the band with a molecular weight of 36 kDa.
N-terminal sequence analysis of the three ␤ 2 GPI preparations revealed a single sequence for ␤ 2 GPI-3 (Gly-Arg-Thr-Cys-Pro-Lys), consistent with normal intact ␤ 2 GPI (9). Analysis of ␤ 2 GPI-1 and ␤ 2 GPI-2 revealed for both preparations two different N-terminal amino acid sequences, with similar molar concentrations, indicating that in these ␤ 2 GPI preparations two N-termini are present. One sequence is identical to the sequence found for ␤ 2 GPI-3. The other sequence (ThrAsp-Ala-Ser-Asp-Val) is identical to that which appears when ␤ 2 GPI is cleaved in the fifth domain between Lys317 and Thr318, as described by Hunt et al. (37) .
In conclusion, heparin-Sepharose affinity chromatography results in three different forms of ␤ 2 GPI: two "cleaved" forms ␤ 2 GPI-1 and ␤ 2 GPI-2, which are designated as ␤ 2 GPI *1 and ␤ 2 GPI *2 , respectively, and one intact form ␤ 2 GPI-3, which is designated as ␤ 2 GPI intact .
Characterization of the Monoclonal anti-␤ 2 GPI-antibodies
The specificity of MoAbs 13A10, 4F3, 2B2 and phage-F3 for the three ␤ 2 GPI forms was tested in an ELISA in which purified ␤ 2 GPI was coated on high-binding 96 wells plates. As shown in Fig. 3 , MoAb 13A10 only recognized ␤ 2 GPI *1 , phage-F3 only recognized ␤ 2 GPI intact , whereas MoAb 4F3 recognized all three forms of ␤ 2 GPI with comparable affinity. ␤ 2 GPI *2 is not recognized by MoAb 13A10 nor by phage-F3. MoAb 2B2 also recognized all three forms of ␤ 2 GPI (data not shown). Unfortunately, we were unable to raise specific MoAb for ␤ 2 GPI *2 . With the different anti-␤ 2 GPI-antibodies, ELISAs were developed with which plasma levels of total ␤ 2 GPI, ␤ 2 GPI intact and ␤ 2 GPI *1 were measured.
Levels of Cleaved and Intact ␤ 2 GPI in Plasmas
1. Healthy controls. Mean levels (± SD) of total ␤ 2 GPI and ␤ 2 GPI intact in plasmas of healthy individuals were 142 ± 30 g/ml and 161 ± 31 g/ml, respectively. Only trace amounts of ␤ 2 GPI *1 (0.1 ± 0.05 g/ml) were detectable (Fig. 4) .
Sepsis/DIC patients and patients treated with streptokinase.
In plasmas of the patients with sepsis/DIC levels of total ␤ 2 GPI (73 ± 38 g/ml) and ␤ 2 GPI intact (65 ± 44 g/ml) were significantly decreased (p <0.0001 and p <0.0001, respectively; student's t-test) compared to the healthy control population (Fig. 4) . Levels of ␤ 2 GPI *1 (1.1 ± 1.2 g/ml) were significantly increased (p <0.0001, student's t-test) compared to the healthy control population. In plasmas of four streptokinase treated patients levels of total ␤ 2 GPI (165 ± 23 g/ml) and ␤ 2 GPI intact (157 ± 15 g/ml) were similar to their respective levels in the control population, whereas levels of ␤ 2 GPI *1 (10 ± 2 g/ml) were approximately 100 times increased (p <0.0001, student's t-test) compared to the control population (Fig. 4) .
3. A patient rescued from drowning. APTT clotting times, levels of D-dimers (as measure of the fibrinolytic activity) and levels of total ␤ 2 GPI, ␤ 2 GPI *1 and ␤ 2 GPI intact were measured in plasma samples of a patient who was hospitalized immediately after being rescued from drowning. Within 10 h after hospitalization the APTT prolonged up to 120 s, paralleled by an increase of plasma D-dimer levels up to 24 mg/ml (Fig. 5A) . During the next 5 days both APTT clotting times and D-dimer levels gradually decrease to normal values. Simultaneous with this activation of the coagulation and fibrinolysis, there was a decrease in levels of total ␤ 2 GPI and ␤ 2 GPI intact to about 30% of the value at admission to the hospital, and an increase in levels of ␤ 2 GPI *1 (Fig. 5B) . When coagulation and fibrinolytic activities were normalizing, there was an increase in levels of total ␤ 2 GPI and ␤ 2 GPI intact and a decrease of levels of ␤ 2 GPI *1 , returning to levels found at hospitalization.
Proteolytical Cleavage of ␤ 2 GPI
To investigate which enzymes are responsible for the cleavage of ␤ 2 GPI intact , purified ␤ 2 GPI intact (200 g/ml) was incubated with plasmin (0.2 M), a protease with known specificity for Lys residues. At different time points samples were taken, treated with PNGase F and subjected to SDS-PAGE. Purified ␤ 2 GPI *1 was used as a control. As shown in Fig. 6 , during plasmin incubation a protein band with a molecular weight of approximately 1 kDa below ␤ 2 GPI intact appeared, indicating that cleaved ␤ 2 GPI (␤ 2 GPI *1 and/or ␤ 2 GPI *2 ) is formed. Within 60 min incubation more than 50% of the ␤ 2 GPI intact was cleaved. N-terminal sequence analysis confirmed that this plasmin treated ␤ 2 GPI is cleaved between residues Lys317 and Thr318. In addition, heparin-Sepharose chromatographic analysis of the plasmin cleaved ␤ 2 GPI product suggests that the plasmin cleaved form of ␤ 2 GPI is similar to ␤ 2 GPI *2 (data not shown).
We also tested the effect of plasmin on ␤ 2 GPI intact bound to a plastic surface. ␤ 2 GPI coated on an ELISA plate, was incubated with increasing concentrations of plasmin for 90 min. Subsequently, coated ␤ 2 GPI was incubated with MoAbs with specificity for the different forms of ␤ 2 GPI. As shown in Fig. 7 , the recognition of coated ␤ 2 GPI by MoAb 4F3 decreases to 55% (at the highest plasmin concentration) of the originally coated ␤ 2 GPI, indicating that upon plasmin incubation part of the coated ␤ 2 GPI is removed from the plastic surface. The recognition by phage-F3 antibodies totally disappeared after incubation with 0.15 M plasmin, indicating that with this plasmin concentration, coated ␤ 2 GPI is totally cleaved by plasmin. However, cleavage of coated ␤ 2 GPI intact by plasmin does not result in the formation of ␤ 2 GPI *1 , because MoAb 13A10 did not recognize the plasmin treated protein. These results strongly suggest that cleavage of coated ␤ 2 GPI by plasmin results in the formation of ␤ 2 GPI *2 and not in the formation of ␤ 2 GPI *1 .
We also tested the proteolytical effect of trypsin, elastase, ␣-thrombin and factor Xa on ␤ 2 GPI coated to an ELISA plate (data not shown). Both trypsin and elastase had similar effect as plasmin, whereas ␣-thrombin and activated factor Xa did not cause a cleavage of ␤ 2 GPI. Fig. 3 Recognition of the different ␤ 2 GPI forms by MoAb 13A10 (A), MoAb 4F3 (B) and phage F3 (C). Increasing concentrations of purified ␤ 2 GPI *1 (b), ␤ 2 GPI *2 () and ␤ 2 GPI *intact (̅), were coated on high binding 96-wells ELISA plates and were assayed for antibody recognition Fig. 4 Plasma levels of total ␤ 2 GPI, ␤ 2 GPI intact and ␤ 2 GPI *1 in sepsis patients (n = 15), streptokinase treated patients (n = 4) and healthy controls (n = 65). Open symbols (ć) correspond to the left y-axis and closed symboils (b) correspond to the right y-axis. Horizontal bars indicate mean ␤ 2 GPI levels
Characteristics of the Different ␤ 2 GPI Preparations
Binding of ␤ 2 GPI to phospholipids. Binding of the three different ␤ 2 GPI preparations to PS/PC/PE (20%/40%/40%) was studied in a solid-phase binding assay, in which PS/PC/PE vesicles were coated on high binding ELISA plates. Fig. 8 shows binding curves of ␤ 2 GPI *1 , ␤ 2 GPI *2 and ␤ 2 GPI intact to immobilized PS/PC/PE. Analysis of the specific binding revealed a ␤ 2 GPI concentration at which half maximal binding was observed of 0.02 M (1 g/ml) for ␤ 2 GPI intact and 0.13 M (6.6 g/ml) for ␤ 2 GPI *2 . For ␤ 2 GPI *1 this concentration could not be determined, because no saturation of binding occurred with the ␤ 2 GPI concentrations used.
Binding of human anti-␤ 2 GPI-IgG to ␤ 2 GPI. The recognition of the three different ␤ 2 GPI preparations by anti-␤ 2 GPI-IgG from a SLE-patient was tested in an ELISA using total IgG purified from the plasma of a patient with high anti-␤ 2 GPI-antibody titres. As shown in Fig. 9A , patient anti-␤ 2 GPI-antibodies bind to all three ␤ 2 GPI preparations, immobilized directly to the ELISA plates, indicating that the epitope for anti-␤ 2 GPI-antibodies is present on all three forms of ␤ 2 GPI.
We next studied the binding of patient anti-␤ 2 GPI-antibodies to the different ␤ 2 GPI preparations bound to cardiolipin. Fig. 9B shows that the amount of bound anti-␤ 2 GPI-antibodies reflects the amount of ␤ 2 GPI bound to the cardiolipin coated well.
Discussion
In 1990 it was shown that the presence of a plasma protein, identified as ␤ 2 GPI, was required for the binding of aPL to negatively charged phospholipids (6, 7) . At that time ␤ 2 GPI was already known as a natural anticoagulant in in vitro experiments. It inhibits the contact ac- tivation of the intrinsic coagulation pathway, both tenase and prothrombinase activity and ADP-induced platelet aggregation (14, (16) (17) (18) (19) (20) (21) (22) . Apart from these anticoagulant effects, ␤ 2 GPI also inhibits the activity of APC, which is one of the most important natural anticoagulants (23, 24) . Whether ␤ 2 GPI is an important anticoagulant or procoagulant factor in vivo is still uncertain, because persons with a ␤ 2 GPI deficiency lack the clinical symptoms of bleeding or thrombosis (25, 26) .
In this study we have found that purified ␤ 2 GPI is very sensitive for proteolytical cleavage, resulting in ␤ 2 GPI which is cleaved in the fifth domain between Lys317 and Thr318. In purified systems, it was found that plasmin, trypsin and elastase are able to cause this specific cleavage. Upon proteolytical cleavage, the phospholipid binding affinity of ␤ 2 GPI decreases (Fig. 8) , which may have consequences for the proposed function(s) of ␤ 2 GPI. It is thought that ␤ 2 GPI inhibits pro-and anticoagulant reactions by shielding of the negatively charged phospholipid surface, which is essential as a template for most coagulation reactions. After plasmin digestion ␤ 2 GPI might be released from these catalytic surfaces, which then results in continuation of different proand anticoagulant reactions. To prevent unwanted cleavage of ␤ 2 GPI during purification, pretreatment of plasma with perchloric acid precipitation is advised. Such treatment will protect ␤ 2 GPI against proteolytical cleavage.
Although we initially discovered the proteolytical cleavage of ␤ 2 GPI during purification (Fig. 1) , we next demonstrated that under certain pathological conditions proteolytically cleaved forms of ␤ 2 GPI can be detected in plasma of patients (Fig. 4) . Clinical syndromes in which these cleaved forms of ␤ 2 GPI circulate were patients suffering from DIC and patients treated with streptokinase. After induction of DIC, illustrated by a prolonged APTT and increase in D-dimer levels in a patient who was rescued from drowning, the plasma level of cleaved ␤ 2 GPI increased up to 6 g/ml (Fig. 5) . Concomitant with the formation of cleaved ␤ 2 GPI a drop of intact ␤ 2 GPI was noticed. The drop of intact ␤ 2 GPI in plasma exceeds the increase in cleaved ␤ 2 GPI. The simultaneous occurrence of an increase of cleaved ␤ 2 GPI and a decrease of intact ␤ 2 GPI, might suggest that the cleavage of ␤ 2 GPI induces a clearance of ␤ 2 GPI. However, in plasmas of the patients treated with streptokinase strongly increased levels of cleaved ␤ 2 GPI are present, in absence of a drop in levels of intact ␤ 2 GPI. This suggests that cleavage of ␤ 2 GPI itself is not the explanation for clearance of ␤ 2 GPI in patients with DIC. In previous reports, it has been suggested that ␤ 2 GPI is involved in the clearance of negatively charged phospholipid liposomes (38) (39) (40) (41) (42) . It was described that in vitro ␤ 2 GPI binds to different kinds of particles expressing negatively charged phospholipids, like apoptotic bodies and oxidised LDL. Therefore, a simple explanation for the disappearance of ␤ 2 GPI from the circulation in patients with DIC is that ␤ 2 GPI binds to negatively charged phospholipids, which are exposed abundantly on apoptotic bodies. These bodies are known to be present in patients with sepsis/DIC (43) (44) (45) (46) .
The observation of high levels of cleaved ␤ 2 GPI in streptokinase treated patients and the observation that in vitro plasmin is able to cleave ␤ 2 GPI, suggests that in vivo plasmin is also responsible for the proteolytic cleavage. Our in vitro experiments showed that cleavage of ␤ 2 GPI by plasmin results in the formation of ␤ 2 GPI *2 ( Fig. 6-7) , which is immunological different from the cleaved form of ␤ 2 GPI (␤ 2 GPI *1 ) that we demonstrated in vivo (Fig. 4) . These findings can point to the presence of an unknown factor in plasma which in vivo immediately converts plasmin cleaved ␤ 2 GPI *2 into ␤ 2 GPI *1 . This assumption is strengthened by the observation that during purification of ␤ 2 GPI from human plasma, both cleaved forms of ␤ 2 GPI are formed (Fig. 1) . Unfortunately, the lack of a specific antibody against ␤ 2 GPI *2 made it impossible to measure the presence of ␤ 2 GPI *2 directly in plasma.
Based on N-terminal sequence analysis and molecular weight determination, however, ␤ 2 GPI *1 and ␤ 2 GPI *2 were found to be identical (Fig. 2) . At this time, we can only speculate about the differences between ␤ 2 GPI *1 and ␤ 2 GPI *2 . It is possible that the difference between the cleaved forms of ␤ 2 GPI is caused by a modification in glycosylation. Alternatively, the immunological differences between ␤ 2 GPI *1 and ␤ 2 GPI *2 , however, may result from differences in tertiary structure. Another explanation might be that the differences between ␤ 2 GPI *1 and ␤ 2 GPI *2 are caused by the presence of different ␤ 2 GPI allotypes.
In conclusion, we have demonstrated for the first time that in vivo ␤ 2 GPI is cleaved between Lys317 and Thr318 during fibrinolysis and that in vitro plasmin could induce this specific proteolytical cleavage. The proteolytical cleavage of ␤ 2 GPI is not required for the observed clearance of ␤ 2 GPI from the circulation in patients with DIC. ␤ 2 GPI is probably removed from the circulation by binding to negatively charged phospholipids, which are exposed on apoptotic cell particles.
After finishing this study, a study from Ohkura et al. (47) was published in which comparable proteolytical effect of plasmin on ␤ 2 GPI was demonstrated. However, the authors did not measure the in vivo occurrence of the intact and cleaved forms of ␤ 2 GPI. Fig. 9 Recognition of different forms of ␤ 2 GPI by human anti-␤ 2 GPI-antibodies. (A) Increasing concentrations purified ␤ 2 GPI intact (̅), ␤ 2 GPI *2 () or ␤ 2 GPI *1 (b) were coated on high binding 96-wells ELISA plates and were incubated with 100 g/ml purified patient IgG. Bound anti-␤ 2 GPI-antibodies were detected with alkaline phosphatase conjugated goat anti-human-IgG. (B) High binding 96-wells ELISA plates were coated with cardiolipin (5 g/well) and were was incubated with 100 g/ml purified patient-IgG, in the presence of increasing concentrations ␤ 2 GPI intact (̅), ␤ 2 GPI *2 () or ␤ 2 GPI *1 (b). Bound anti-␤ 2 GPI-antibodies were detected with alkaline phosphatase conjugated goat anti-human-IgG. Results are expressed as mean ± SD of three individual experiments
